Outlook Therapeutics finishes patient registration for NORSE 1 trial
Category: #health  By Pankaj Singh  Date: 2019-08-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Outlook Therapeutics finishes patient registration for NORSE 1 trial
  • NORSE 1 has registered a sum of 61 patients from nine different sites in Australia.
     
  • This study is first of the two current, well controlled and adequate Phase 3 clinical trials examining ONS-5010 for wet AMD.

Outlook Therapeutics Inc., a clinical stage biopharmaceutical organization aimed at commercializing and developing ONS-5010, a commercially attractive antibody and ophthalmic bevacizumab product to treat wet age-related macular degeneration (wet AMD) as well as few other retina diseases, reportedly announced the completion of enrollment of patients for NORSE 1 Phase 3 clinical trial, a study that is examining ONS- 5010 for wet AMD against ranibizumab (Lucentis®).

NORSE 1 has registered approximately 61 patients from nine different sites in Australia. This study is first of the two current, well controlled and adequate Phase 3 clinical trials examining ONS-5010 against ranibizumab (Lucentis®) for wet AMD.

The final point of the study is average change in the baseline of visual acuity at approximately 11 months for ONS-5010 administered once in a month compared to ranibizumab (Lucentis®) dosed utilizing the PIER alternate medicating regimen of three doses in a month which will be followed by quarterly doses. The company is expecting to unveil the topline output of NORSE 1 by the third quarter of next year.

Chief Financial Officer, Chief Executive Officer and President of Outlook Therapeutics, Lawrence A. Kenyon stated that company is pleased with increasing momentum in its two current Phase 3 clinical trials of ONS-5010, which includes enrollment completion in NORSE 1.

Kenyon added that reaching this milestone keeps the company on track to achieve its aim of submitting ONS-5010 in the United States for regulatory approval next year.

The success of ONS-5010 would help Outlook’s aim of submitting it for regulatory approval across multiple markets next year. If permitted, ONS-5010 is capable to mitigate risks connected with off-label consumption of Avastin and some other drugs.

Avastin drug’s off-label use is estimated to be 50% in the United States among all the wet AMD prescriptions.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...